Recipharm has entered into a long term supply agreement with Tillotts Pharma AG for the technology transfer and commercial manufacture of Entocort and Asacol. The agreement will also involve the commercial scale development of Tillotts’ ongoing development program for TP05. All products are part of Tillotts’ gastroenterology therapies.
 
Recipharm will provide pellet coating technology for controlled release from its facility in Pessac, France, tablet and capsule manufacturing including final packaging from its facility in Fontaine, France, and bottle filling from its site in Lisbon, Portugal. The total shared investment across the Recipharm network amounts to €3.5 million and includes investments to create new capacity as well as product specific investments.
 
Kjell Johansson, president manufacturing services Europe at Recipharm, said, “We are really pleased that Tillotts Pharma AG has chosen Recipharm for these exciting products and projects. Our technical solutions offer a high level of customization and we look forward to working with Tillotts to ensure their continued development and success within the gastroenterology area.” 
 
Mattias Norrman, chief operating officer of Tillotts Pharma AG, said, “We have undertaken a thorough evaluation process to ensure we partner with a CDMO that can meet the needs we have for project management during technology transfer and scale-up, as well as fulfilling our requirements as a reliable commercial supplier. We believe Recipharm is the ideal CDMO partner for this task and look forward to establishing a long term relationship.”